Butyl 4-(butyryloxy)benzoate functions as a new selective estrogen receptor β agonist and induces GLUT4 expression in CHO-K1 cells

Estrogen receptors (ERs) belong to nuclear hormone receptor superfamily and can be activated by estrogens and regulate many target genes. Two ER isoforms, ERalpha and ERbeta have been discovered to date and ERbeta was indicated to involve in anti-inflammatory and anti-diabetogenic effects. Recently, some studies also demonstrated an association between ERbeta and GLUT4 expression. The development of selective ERbeta ligand has facilitated probing its novel biological functions and clinical benefits. In this work, a new ERbeta selective agonist, butyl 4-(butyryloxy)benzoate (DCW234), was discovered as investigated by surface plasmon resonance (SPR) technology, yeast two-hybrid and cell-based transcription-based assays. SPR results demonstrated that DCW234 has a higher binding affinity against ERbeta over ERalpha and induces a strong and selective stimulation on ERbeta/SRC1 interaction, which could be efficiently blocked by Tamoxifen. Meanwhile, the yeast two-hybrid technology-based assay indicated that DCW234 exhibits a higher agonistic activity ( approximately 13-fold) in stimulating ERbeta ligand-binding domain (LBD) interaction with SRC1 (EC(50)=2.5 microM) than ERalpha-LBD/SRC1 interaction (EC(50)=32.7 microM). The cell-based transcriptional assay further proved the potency and selectivity of DCW234. Moreover, DCW234 was found to be able to induce GLUT4 expression in CHO-K1 cell. The discovered DCW234 might be hopefully developed as a potential lead compound for further research.

[1]  H. Harris,et al.  Estrogen receptor-beta: recent lessons from in vivo studies. , 2007, Molecular endocrinology.

[2]  J. Gustafsson,et al.  Estrogen receptors: new players in diabetes mellitus. , 2006, Trends in molecular medicine.

[3]  I. Godsland,et al.  Oestrogens and insulin secretion , 2005, Diabetologia.

[4]  K. Korach,et al.  Lessons in estrogen biology from knockout and transgenic animals. , 2005, Annual review of physiology.

[5]  J. Polman,et al.  ER beta: identification and characterization of a novel human estrogen receptor. , 1996, FEBS letters.

[6]  D. Livingston,et al.  The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  K. Kaestner,et al.  Mouse insulin-responsive glucose transporter gene: characterization of the gene and trans-activation by the CCAAT/enhancer binding protein. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study , 2004 .

[9]  M Carlquist,et al.  Structure of the ligand‐binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist , 1999, The EMBO journal.

[10]  D. Purdie,et al.  The selective oestrogen receptor modulation: evolution and clinical applications. , 1999, British journal of clinical pharmacology.

[11]  J. Gustafsson,et al.  Muscle GLUT4 regulation by estrogen receptors ERβ and ERα , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Komm,et al.  Evaluation of an estrogen receptor-beta agonist in animal models of human disease. , 2003, Endocrinology.

[13]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[14]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[15]  J. Gustafsson,et al.  Muscle GLUT4 regulation by estrogen receptors ERbeta and ERalpha. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  U. Schopfer,et al.  Toward selective ERbeta agonists for central nervous system disorders: synthesis and characterization of aryl benzthiophenes. , 2002, Journal of medicinal chemistry.

[17]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[18]  David M. Heery,et al.  A signature motif in transcriptional co-activators mediates binding to nuclear receptors , 1997, Nature.

[19]  M. T. Nunes,et al.  NF-κB, MEF2A, MEF2D and HIF1-a involvement on insulin- and contraction-induced regulation of GLUT4 gene expression in soleus muscle , 2005, Molecular and Cellular Endocrinology.

[20]  Heather A. Harris,et al.  Estrogen Receptor- (cid:1) : Recent Lessons from in Vivo Studies , 2006 .

[21]  Z. Keidar,et al.  Effects of tamoxifen on bone mineral density and metabolism in postmenopausal women with early-stage breast cancer , 2004, Medical oncology.

[22]  C. Christiansen,et al.  EFFECTS OF RALOXIFENE ON BONE MINERAL DENSITY, SERUM CHOLESTEROL CONCENTRATIONS, AND UTERINE ENDOMETRIUM IN POSTMENOPAUSAL WOMEN , 1998 .

[23]  B. Katzenellenbogen,et al.  Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. , 2001, Journal of medicinal chemistry.

[24]  B. Komm,et al.  Evaluation of an Estrogen Receptor-β Agonist in Animal Models of Human Disease , 2003 .

[25]  H. Harris.  The unexpected science of estrogen receptor-β selective agonists: a new class of anti-inflammatory agents? , 2006, Nuclear receptor signaling.

[26]  B. O’Malley,et al.  Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.

[27]  J. Gustafsson,et al.  Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. , 1997, Endocrinology.

[28]  Zbigniew Dauter,et al.  Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.

[29]  K. Korach,et al.  Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. , 2002, Molecular endocrinology.

[30]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[31]  R. D. Gietz,et al.  Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. , 2002, Methods in enzymology.

[32]  R B Mazess,et al.  Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. , 1992, The New England journal of medicine.

[33]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[34]  J. Shine,et al.  Sequence and expression of human estrogen receptor complementary DNA. , 1986, Science.

[35]  P. Kushner,et al.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.

[36]  Ann Cranney,et al.  Benefit-Risk Assessment of Raloxifene in Postmenopausal Osteoporosis , 2005, Drug safety.

[37]  J. Polman,et al.  ERβ: Identification and characterization of a novel human estrogen receptor , 1996 .

[38]  Iwan Gunawan,et al.  Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. , 2004, Journal of medicinal chemistry.

[39]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Korach,et al.  Estrogen receptors and human disease. , 2006, The Journal of clinical investigation.

[42]  M. Stallcup,et al.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.